Early research (Phase 1)WithdrawnNCT04958967What this trial is testingPhase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion MutationWho this might be right forNSCLC Allist Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)UnknownNCT01749072What this trial is testingVinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer PatientsWho this might be right forNon-small Cell Lung CancerEffects of Chemotherapy Peking Union Medical College Hospital 120
Testing effectiveness (Phase 2)Study completedNCT01204307What this trial is testingInfluence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene MutationWho this might be right forAdvanced Non-Squamous Non-Small Cell Lung Cancer Chang Gung Memorial Hospital 101
Testing effectiveness (Phase 2)Study completedNCT03434418What this trial is testingA Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR MutationsWho this might be right forNon Small Cell Lung Cancer Duke University 17
Testing effectiveness (Phase 2)UnknownNCT05813522What this trial is testingFurmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLCWho this might be right forNon Small Cell Lung Cancer First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)WithdrawnNCT01504542What this trial is testingImmune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Heat Biologics
Testing effectiveness (Phase 2)Study completedNCT01513174What this trial is testingStudy With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib AloneWho this might be right forNon Small Cell Lung Cancer Spanish Lung Cancer Group 186
Large-scale testing (Phase 3)Study completedNCT02296125What this trial is testingAZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerWho this might be right forLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer AstraZeneca 674
Testing effectiveness (Phase 2)Active Not RecruitingNCT03808662What this trial is testingRandomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and LungWho this might be right forTNBC - Triple-Negative Breast CancerTriple Negative Breast CancerNSCLC+4 more Memorial Sloan Kettering Cancer Center 107
Testing effectiveness (Phase 2)UnknownNCT04358562What this trial is testingGefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibWho this might be right forNon-small Cell Lung CancerEGFR Gene Mutation Second Affiliated Hospital of Nanchang University 240
Not applicableStudy completedNCT02623257What this trial is testingEGFR Mutations on ctDNA in Patients With Advanced NSCLCWho this might be right forNon-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic First People's Hospital of Hangzhou 1,055
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992What this trial is testingAlflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）Who this might be right forLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer Allist Pharmaceuticals, Inc. 358
Large-scale testing (Phase 3)Active Not RecruitingNCT04351555What this trial is testingOsimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer AstraZeneca 358
Testing effectiveness (Phase 2)Study completedNCT01580735What this trial is testingARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung CancerWho this might be right forNon-small-cell Lung Cancer Kyowa Kirin Co., Ltd. 40
Large-scale testing (Phase 3)Looking for participantsNCT07100080What this trial is testingStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)Who this might be right forNon-Small Cell Lung Cancer Bristol-Myers Squibb 500
Testing effectiveness (Phase 2)Study completedNCT01415011What this trial is testingEfficacy and Safety Study of Afatinib to Treat Lung Cancer PatientsWho this might be right forCarcinoma, Non-Small-Cell Lung University College, London 39
Large-scale testing (Phase 3)Looking for participantsNCT06956001What this trial is testingFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationWho this might be right forEGFRNSCLC (Advanced Non-small Cell Lung Cancer) Allist Pharmaceuticals, Inc. 300
Testing effectiveness (Phase 2)UnknownNCT03502850What this trial is testingSafety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung CancerWho this might be right forLocally Advanced or Metastatic NSCLC Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Testing effectiveness (Phase 2)UnknownNCT02820116What this trial is testingThe Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR MutationWho this might be right forNon-small Cell Lung Cancer(NSCLC) Beijing Haidian Hospital 67
Large-scale testing (Phase 3)UnknownNCT04239833What this trial is testingSH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer Nanjing Sanhome Pharmaceutical, Co., Ltd. 240